Introduction
Cardiac amyloidosis is an unusual cause of heart failure in the general population, but is a common complication of systemic AL amyloidosis. Most patients with AL amyloidosis and symptomatic heart failure are not candidates for autologous stem cell transplantation and carry the worst prognosis. 1 There is substantial variation in the estimated incidence of cardiac amyloidosis in patients with AL amyloidosis, ranging from 50% to 65% based on clinical criteria to 90% based on pathology. [1] [2] [3] As heart failure remains the most common cause of mortality in patients with systemic AL amyloidosis, early detection and ongoing assessment of cardiac involvement has become an important means to assess therapeutic response. 4, 5 The current NCCN criteria including troponin, NT-proBNP, and echocardiography for assessment of cardiac involvement and staging in patients with systemic AL amyloidosis were proposed in 2004, 4 but there are limited data on the utilization of these criteria in clinical practice. In the present study, we retrospectively reviewed the medical record of patients with biopsy-proven AL amyloidosis between 2006 and 2011 in our institution. The aims of this study were to assess the prevalence of cardiac involvement based on the International Cardiovascular Forum Journal 6 (2016) DOI: 10.17987/icfj.v6i0.172
clinical diagnosis at the time of the diagnosis of AL amyloidosis, the prevalence of cardiac involvement based on the NCCN criteria, and the clinical implementation of the NCCN guidelines-recommended routine testing and follow-up.
Methods
The Institutional Review Board of the New York University School of Medicine approved the study protocol. ICD-9 diagnosis code 277.30 was used to identify the patients with a diagnosis of amyloidosis. 28 patients with biopsy-proven AL amyloidosis were identified between 2006 to 2011 from New York University Medical Center. Surgical pathology reports from organ biopsies including abdominal fat, kidney, liver, heart, duodenum, and colon were reviewed. Tissue involvement was confirmed based on positive Congo red staining, apple-green birefringence from polarized light, and/or electronic microscopic detection of amyloid fibrils in pathology specimens. The results from bone marrow biopsy and serum/urine immunofixation were recorded. Relevant demographic data and medical history were extracted from electronic medical records. All electrocardiograms and echocardiograms were reviewed. Serum free light chain (FLC), Troponin I (TnI), and N-terminal pro-brain natriuretic peptide (NT-proBNP) were recorded if available. Echocardiography, NT-proBNP and TnI measurements within 3 months of diagnosis of AL amyloidosis were considered to be part of the initial evaluation of cardiac involvement. New York Heart Association (NYHA) Class was obtained from the history of present illness at admission or clinic notes within 3 months of diagnosis. The diagnostic criteria used in this project are listed below:
1. Clinical diagnosis of cardiac amyloidosis is defined as symptomatic heart failure (NYHA Class II-IV) without other causes. 2. The current NCCN Guidelines Version 2.2014 is used for reassessment of cardiac involvement. The NCCN criteria for cardiac involvement is defined by mean wall thickness >12 mm without other cardiac cause from echocardiography or elevated NT-proBNP (>332 pg/ml) in the absence of renal failure or atrial fibrillation. 3. Elevated TnI is defined as more than two times of upper normal limit (0.04 ng/ml in our laboratory). 4. Low voltage on 12-lead ECG was defined by QRS complex amplitude <0.5mV in each limb lead or < 1mV in each precordial lead, or V1 S wave plus V5 or V6 R wave <1mV. Mortality outcomes over time were assessed with the Kaplan-Meier method and the log-rank test was used to assess differences between survival curves. A 2-tailed p value < 0.05 was considered statistically significant.
Results
A total 28 patients with biopsy-proven AL amyloidosis were included for the final analysis (Table 1 ). There were 9 women and 19 men in the cohort (mean age was 64.8 ± 9.9 years, 22 patients with lambda light chain amyloid and 6 patients with Kappa light chain amyloid). 12 patients died (43%) with a median survival 153 days.
Prevalence of cardiac amyloidosis and outcomes based on clinical diagnosis and NCCN criteria.
Fourteen patients (50%) carried a clinical diagnosis of cardiac amyloidosis at the time of the diagnosis of AL amyloidosis. All 14 patients presented with clinical heart failure with NYHA Class II-IV and were referred to a cardiologist. All 14 patients also met the NCCN criteria for cardiac involvement. Clinical characteristics of the patients with and without a clinical diagnosis of cardiac amyloidosis are summarized in Table 2 . The majority of patients (77%) with clinical diagnosis of cardiac amyloidosis had elevated troponin. Patients with a clinical diagnosis of cardiac amyloidosis had greater risk of death during follow-up when compared with those without a clinical diagnosis of cardiac amyloidosis (9 vs. 3 deaths, p=0.02, Figure 1 ). All the patients who died had either elevated NT-proBNP or TnI or both at the time of the diagnosis, except one patient in whom NT-proBNP was not measured (Table 1) .
When we reevaluated the remaining 14 patients by using the NCCN criteria, 4 patients met the criteria for cardiac involvement either based on mean wall thickness >12 mm or elevated NT-ProBNP or both (Study ID 21, 22, 23, 24). None of these 4 patients were referred to cardiologist. 3 additional patients (Study ID 3, 20, 26) also met the NCCN criteria of cardiac involvement, but had known history of coronary artery disease and/or myocardial infarction. One of these patients (Study ID 3) with elevated NT-proBNP and TnI presented with heart failure and had significant multi-vessel coronary artery disease confirmed by coronary angiogram. In the other 2 patients (Study ID 20 and 26), TnI was persistently elevated without other evidence of acute coronary syndrome, and is therefore consistent with the diagnosis of cardiac amyloidosis. Accordingly, 6 patients without a clinical diagnosis of cardiac amyloidosis met the NCCN criteria for cardiac involvement.
Three patients (study ID 6, 12, 16) did not have echocardiography and NT-proBNP documented and could not be evaluated. Four patients (Study ID 7, 11, 19, 28) had no evidence of cardiac involvement based on the NCCN criteria.
In total, 20 patients (20/28, 71.4%) had cardiac amyloidosis or cardiac involvement by either clinical diagnosis or the NCCN criteria.
Biomarkers utilization in the initial evaluation
Thirteen of 28 patients (46.4%) had NT-proBNP measured as a part of initial evaluation. All but one of these patients had elevated NT-proBNP levels. Eight of 14 patients (57%) with clinical diagnosis of cardiac amyloidosis had NT-proBNP measured as the initial evaluation. 
Discussion
AL amyloidosis is a monoclonal plasma cell dyscrasia associated with over production of amyloidogenic light chain, which acts as the precursor protein and is able to misfold into fibrils. 6 Deposition of these amyloid fibrils in visceral tissues may result in cardiomyopathy, nephropathy, hepatomegaly, and peripheral neuropathy. Overall survival of patients with AL has been improving over the last 30 years. However, 1-year mortality remains high, especially in the group of patients with cardiac involvement and with elevated troponin and / or NT-proBNP. 7 Cardiac involvement is the most important determinant of the prognosis of patients with AL amyloidosis.
In our study sample, cardiac amyloidosis diagnosed based on symptomatic heart failure was present in 50% of patients at the time of diagnosis of AL amyloidosis. More than half of these patients died during follow-up. When we assessed all the patients by using the current NCCN criteria of cardiac involvement in amyloidosis, the prevalence rises to 71.4% (20/28). This could be underestimated due to a lack of echocardiographic and NT-pro-BNP data in 3 patients. The high prevalence of cardiac involvement and high risk of mortality in symptomatic patients is consistent with prior reports.
In 2004, Dispenzieri and colleagues introduced a cardiac staging system based on two cardiac biomarkers, TnI and NT-proBNP. 4 Patients with significant elevations of both biomarkers have a median survival of only 3.5 months. If one biomarker is elevated, the median survival is 10.5 months. This staging system was further studied and modified by including serum free light chain. 8 The measurement of TnI and NT-proBNP is recommended in the initial evaluation for AL amyloidosis. Our study confirmed the prognostic value of these two biomarkers in AL amyloidosis. The majority of patients (77%) with clinical diagnosis of cardiac amyloidosis had elevated troponin. All the patients who died had either elevated NT-proBNP or TnI level or both at the time of the diagnosis except one who did not have NT-proBNP tested. However, routine use of these biomarkers has not been uniformly incorporated into clinical practice. In our cohort, <40% of the patients had NT-proBNP testing and approximately 70% had Tnl testing as the initial part cardiac evaluation. Three patients did not have biomarker or imaging testing at the time of diagnosis with AL amyloidosis. The reduction of serum FLC has been proposed and validated as a key element of hematologic response to the treatment and it has a significant prognostic role. 2, 8 However, the FLC testing has not been routinely applied into the clinical practice as shown in our series that only 6 of 28 patients had baseline and follow-up of measurements of FLC despite the fact that this test was available in 2006.
The prognosis of patients with AL amyloidosis mainly depends on the cardiac involvement or the burden of the amyloid in the heart. NT-proBNP or BNP, troponins, and echocardiography have been recommended as main tools to diagnose cardiac amyloidosis and assess the extent of cardiac involvement. 9 NT-proBNP and troponin are accepted as the best means to stage patients with AL amyloidosis. 4 These have also been recommended as the follow-up tests to assess the cardiac response to the therapies. 10 Our study showed that the diagnosis of cardiac involvement was still mainly based on the clinical heart failure symptoms and the recommended testing and follow-up were not routinely applied into the clinical practice.
Our data are derived from a single institution and might not be representative of national practice patterns in the United States. The high prevalence of cardiac involvement is consistent with prior reports. The previous study shows patients with AL amyloidosis who present with clinical heart failure or syncope have median survival of 4 to 6 months; 11 the majority of these patients are not candidates for autologous stem cell transplantation. 1 Given the known high cardiac mortality risk in patients with AL amyloidosis, more consistent application of existing criteria into clinical practice could increase early diagnosis of cardiac involvement and provide opportunity for interventions including autologous stem cell transplantation that could increase the survival of patients. Cardiac magnetic resonance imaging may also be a sensitive modality for early detection of cardiac involvement in patients with systemic AL amyloidosis.
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Conclusions
In summary, in our single center cohort, the cardiac involvement of AL amyloidosis is underdiagnosed. The guidelines-recommended testing for the diagnosis of cardiac involvement and follow-up for cardiac response to the amyloidosis treatment were not routinely implemented in the clinical practice. Since AL amyloidosis is an uncommon disease with an estimate of incidence of 2000-3000 new cases per year in US, 13 limited clinical experience among practitioners may be a barrier to implementation of optimal care in this population. Creation of institutional multidisciplinary programs with specialized hematology and cardiology expertise may be considered to increase adherence to the guideline recommended care in these high-risk patients.
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Figure1. Kaplan-Meier estimates for probability of death in patients with and without clinical diagnosis of cardiac amyloidosis. 
